Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences' Revenues Up in Q2

NEW YORK (GenomeWeb News) – Pressure BioSciences today reported that its second-quarter 2009 revenues more than doubled year over year, while the firm trimmed its net loss in half.

The South Easton, Mass.-based firm brought in revenues of $270,381 for the three-month period ended June 30, compared to $120,184 for the second quarter of 2008. Sales of its pressure cycling technology products and services rose 35 percent to $159,202 from $117,698.

The company cut its net loss in half to $814,049, or $.39 per share, from $$1.6 million, or $.72 per share.

Its R&D spending decreased to 4315,046 from $461,672 year over year, while its SG&A expenses dropped from $1.2 million to $679,848 — the results of a cost-containment and restructuring program begun last year.

Pressure BioSciences finished the quarter with $1.5 million in cash, cash equivalents, and restricted cash. Its cash burn rate was $663,000 for the second quarter, and the firm hopes to reduce its average quarterly burn rate for 2009 to around $600,000.

Pressure BioSciences' shares were up 4 percent at $1.79 in mid-afternoon trade on the Nasdaq.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.